Table 2. Clinicopathologic characteristics of the patients.
| Characteristic | Total (N=1,367) | CONUT | P | |
|---|---|---|---|---|
| Low | High | |||
| Age (years) | <0.001* | |||
| <48 | 682 (49.9%) | 476 (34.8%) | 206 (15.1%) | |
| ≥48 | 685 (50.1%) | 583 (42.6%) | 102 (7.5%) | |
| Histological type | 0.599 | |||
| Invasive ductal carcinoma | 1,149 (84.1%) | 893 (65.3%) | 256 (18.7%) | |
| Others | 213 (15.6%) | 163 (11.9%) | 50 (3.7%) | |
| Unknown | 5 (0.4%) | 3 (0.2%) | 2 (0.1%) | |
| T stage | 0.229 | |||
| 0 | 2 (0.1%) | 1 (0.1%) | 1 (0.1%) | |
| 1 | 478 (35.0%) | 371 (27.2%) | 107 (7.8%) | |
| 2 | 748 (54.7%) | 588 (43.0%) | 160 (11.7%) | |
| 3 | 68 (5.0%) | 51 (3.8%) | 17 (1.2%) | |
| 4 | 71 (5.2%) | 48 (3.5%) | 23 (1.7%) | |
| N stage | 0.266 | |||
| 0 | 714 (52.2%) | 567 (41.5%) | 147 (10.7%) | |
| 1 | 355 (26.0%) | 272 (19.9%) | 83 (6.1%) | |
| 2 | 171 (12.5%) | 126 (9.2%) | 45 (3.3%) | |
| 3 | 127 (9.3%) | 94 (6.9%) | 33 (2.4%) | |
| M stage | 0.022* | |||
| 0 | 1,340 (98.0%) | 1,043 (76.3%) | 297 (21.7%) | |
| 1 | 27 (2.0%) | 6 (1.2%) | 11 (0.8%) | |
| pTNM stage | 0.027* | |||
| I | 324 (23.7%) | 255 (18.7%) | 69 (5.0%) | |
| II | 694 (50.8%) | 550 (40.3%) | 144 (10.5%) | |
| III | 322 (23.6%) | 238 (17.5%) | 84 (6.1%) | |
| IV | 27 (2.0%) | 16 (1.2%) | 11 (0.8%) | |
| ER | 0.276 | |||
| Negative | 427 (31.2%) | 323 (23.6%) | 104 (7.6%) | |
| Positive | 940 (68.8%) | 736 (53.9%) | 204 (14.9%) | |
| PR | 0.823 | |||
| Negative | 534 (39.1%) | 412 (30.2%) | 122 (8.9%) | |
| Positive | 833 (60.9%) | 647 (47.3%) | 186 (13.6%) | |
| HER2 | 0.986 | |||
| Negative | 973 (71.2%) | 754 (55.2%) | 219 (16.0%) | |
| Positive | 386 (28.2%) | 299 (21.9%) | 87 (6.4%) | |
| Unknown | 8 (0.6%) | 6 (0.4%) | 2 (0.1%) | |
| Ki-67 | 0.034* | |||
| ≤14% | 498 (36.4%) | 370 (27.1%) | 128 (9.4%) | |
| >14% | 869 (63.6%) | 698 (50.4%) | 180 (13.2%) | |
| Molecular subtype | 0.353 | |||
| Luminal A | 353 (25.8%) | 264 (19.3%) | 89 (6.5%) | |
| Luminal B/HER2- | 404 (29.6%) | 326 (23.9%) | 78 (5.7%) | |
| Luminal B/HER2+ | 202 (14.8%) | 160 (11.7%) | 42 (3.1%) | |
| HER2 Enriched | 185 (13.5%) | 140 (10.2%) | 45 (3.3%) | |
| Triple Negative | 217 (15.9%) | 166 (12.2%) | 51 (3.7%) | |
| Unknown | 5 (0.4%) | 3 (0.2%) | 2 (0.1%) | |
| Preoperative CEA | 0.850 | |||
| Negative | 1,190 (87.1%) | 924 (67.6%) | 267 (19.5%) | |
| Positive | 119 (8.7%) | 93 (6.8%) | 26 (1.9%) | |
| Unknown | 57 (4.2%) | 42 (3.1%) | 15 (1.1%) | |
| Preoperative CA153 | 0.255 | |||
| Negative | 1,150 (84.1%) | 900 (65.8%) | 250 (18.3%) | |
| Positive | 161 (12.3%) | 117 (8.6%) | 44 (3.2%) | |
| Unknown | 56 (4.1%) | 42 (3.1%) | 14 (1.0%) | |
*P<0.05. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; CEA, carcinoembryonic antigen; CA153, cancer antigen 153.